Anzeige
Mehr »
Login
Samstag, 27.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Geheimtipp: Rasanter Aufstieg, Branchenrevolution und Jahresumsatz von 50 Mio. $
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
35 Leser
Artikel bewerten:
(0)

Kenrico Announces Financial Results for 2010 and Financial Targets for 2011

SHIMADA, Japan, Nov. 1, 2011 /PRNewswire/ -- Kenrico today announced the disclosure of financial results for the year 2010 and financial targets for the year 2011.

Select Revenue Heights

Worldwide sales were $102 million for the year 2010, the highest yearly sales total for the company, an increase of 2% compared with 2009 ($100 million) and an increase of 24% compared with 2008 ($82 million).

The revenue increase largely reflects strong sales of sporopollenin based toxins extraction (TRMX-3), nattokinase based toxins extraction (Lexirin), Carbon Titanium and Lifetime Water Purifiers. As expected, successful clinical trials of the TRMX-3 contributed to the revenue increase. Nutraceutical and pharmaceutical sales from emerging markets accounted for 40% of sales of the year.

Key Developments

  • TRMX-3 (Supreme Edition), the company's sporopollenin based toxins extractor, was approved by Health Canada in Canada and in Europe by European Medical Device Agency. Separately, the company entered into strategic agreements with pharmaceutical companies to market nattokinase based Lexirin globally to physician for prevention of cell death. Apoptotic cell death plays a significant role in the tissue damage that occurs in association with aging and various abnormal conditions, for example, ischemia and various gastrointestinal disorders.

  • TRMX-3 and Lexirin received patent approval for global distribution.

Financial targets

Kenrico continues to expect full year 2011 revenue to grow in the low to mid single digit percent range from a base of $100 million in 2010.

In addition, the company updated its anticipated consolidated tax rate to range of 10 percent.

About Kenrico

Kenrico is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1985, Kenrico currently discovers, develops, manufactures and markets prescription and alternative medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Kenrico medicines but help deliver them to the people who need them. Kenrico also publishes unbiased health information as a not-for-profit service. For more information, visit www.kenrico.com.

Media Contact
NURMAN SALIM
Phone: +81-547-47-3220
Email: kenrico@kenrico.com

SOURCE Kenrico

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2011 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.